Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir among COVID-19 community, highly vaccinated patients with high risk for severe disease: evidence …
D Paraskevis, M Gkova, K Mellou, G Gerolymatos… - medRxiv, 2023 - medrxiv.org
Besides the significant benefits of vaccination against COVID-19, the risk of severe disease
and death from COVID-19 among highly vulnerable populations remains of concern …
and death from COVID-19 among highly vulnerable populations remains of concern …
Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir as treatments for COVID-19 in patients at high risk
D Paraskevis, M Gkova, K Mellou… - The Journal of …, 2023 - academic.oup.com
Background Using a retrospective cohort study design, we aimed to evaluate the
effectiveness of molnupiravir and nirmatrelvir/ritonavir in patients with SARS-CoV-2 who …
effectiveness of molnupiravir and nirmatrelvir/ritonavir in patients with SARS-CoV-2 who …
Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir against mortality, hospitalization, and in-hospital outcomes among community-dwelling, ambulatory …
Background Evidence evaluating real-world effectiveness of oral antivirals against Omicron
variants is lacking. Methods An unselected, territory-wide cohort of all initially non …
variants is lacking. Methods An unselected, territory-wide cohort of all initially non …
Early access to oral antivirals in high-risk outpatients: good weapons to fight COVID-19
G Bruno, M Giotta, S Perelli, G De Vita, N Bartolomeo… - Viruses, 2022 - mdpi.com
Introduction: Molnupiravir and Nirmatrelvir/r (NMV-r) have been proven to reduce severe
Coronavirus Disease 2019 (COVID-19) in unvaccinated high-risk individuals. Data …
Coronavirus Disease 2019 (COVID-19) in unvaccinated high-risk individuals. Data …
Real-world experience of the comparative effectiveness and safety of molnupiravir and nirmatrelvir/ritonavir in high-risk patients with COVID-19 in a community setting
Y Mutoh, T Umemura, T Nishikawa, K Kondo, Y Nishina… - Viruses, 2023 - mdpi.com
Molnupiravir (MOV) and nirmatrelvir/ritonavir (NMV/r) are efficacious oral antiviral agents for
patients with the 2019 coronavirus (COVID-19). However, little is known about their …
patients with the 2019 coronavirus (COVID-19). However, little is known about their …
Effectiveness of nirmatrelvir/ritonavir and molnupiravir in non-hospitalized adults with COVID-19: systematic review and meta-analysis of observational studies
Objective To determine the effectiveness of nirmatrelvir/ritonavir and molnupiravir among
vaccinated and unvaccinated non-hospitalized adults with COVID-19. Methods …
vaccinated and unvaccinated non-hospitalized adults with COVID-19. Methods …
Comparative effectiveness of nirmatrelvir/ritonavir versus sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised high-risk …
Background Timely evidence of the comparative effectiveness between COVID-19 therapies
in real-world settings is needed to inform clinical care. This study aimed to compare the …
in real-world settings is needed to inform clinical care. This study aimed to compare the …
Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir during the …
Background Comparative data on mortality in COVID-19 patients treated with molnupiravir
or with nirmatrelvir plus ritonavir are inconclusive. We therefore compared all-cause …
or with nirmatrelvir plus ritonavir are inconclusive. We therefore compared all-cause …
Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir among COVID-19 inpatients during Hong Kong's Omicron BA. 2 wave: an observational study
Background Real-world evidence on the effectiveness of oral antivirals in mild-to-moderate
COVID-19 patients is urgently needed. This retrospective cohort study aims to evaluate the …
COVID-19 patients is urgently needed. This retrospective cohort study aims to evaluate the …
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label …
Background The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral
antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the …
antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the …